Insulet announced major updates to the Omnipod 5 automated insulin delivery system coming in 2026 during its first investor day. We previously reviewed Omnipod 5 and noted its strengths in ease of use, automation, and overall stability with room for improvement for its algorithm. These new updates suggest the system is about to take an even bigger step forward, with the company focusing on tighter glucose control, stronger automation, and expanded CGM support. The company also announced a new data tools to deepen the overall experience for users and healthcare providers (HCPs).

One of the most notable changes is the planned reduction of the system’s default glucose target from 110 mg/dL down to 100 mg/dL. This adjustment has been a consistent request from users and clinicians who want tighter control without compromising safety. The target matches the Medtronic 780G’s and is a bit higher than the new twiist AID system. Insulet said the lower target will be paired with a series of algorithm improvements designed to improve adaptation, boost stability, and increase the amount of time users spend in automated mode.

The company also described upgrades meant to extend the time Podders remain in automation. While details were limited, this update appears aimed at keeping the system in closed loop more consistently during moments that typically cause interruptions, such as workouts, illness, or unannounced meals. If successful, it could lead to better handling of unpredictable glucose patterns.

Another significant development is the expansion of CGM compatibility. Insulet confirmed that by the first half of 2026, Omnipod 5 will work with all major continuous glucose monitors, including Abbott’s Freestyle Libre 3 Plus. This expanded support has been one of the most frequently requested enhancements and will give users more freedom to build the setup that works best for them.

As part of the 2026 updates, Insulet will also introduce Discover, a new insights platform that uses machine learning to help users and clinicians make sense of glucose and insulin trends. Discover is already in limited use at select clinics in the U.S. and is designed to simplify therapy review, highlight meaningful patterns, and reduce the amount of time spent sorting through data. Once fully launched, it will support Omnipod 5, Omnipod DASH, and likely Omnipod 6 which the company says will arrive in 2027.

Together, these updates move Omnipod 5 forward in a noticeable way. For a full breakdown of everything Insulet announced,keep an eye out for our full rundown coming later this week for All Access members, which takes a deeper look at what is coming with Omnipod 6, a Fully Closed Loop type 2 diabetes algorithm in-development and innovations beyond 2028.

Disclaimer: Diabetech content is not medical advice—it’s for educational purposes only. Always consult with a physician before making changes to your healthcare.